Production process moved to Irish base

GENZYME, the US-based biotechnology company, is to move the final stages of the production process for its leading Cerezyme treatment to its Irish operation in Waterford.

The powder base of the drug — which is an enzyme replacement treatment for Gaucher disease — will be transformed into tablet form at the company’s Waterford facility.

Gaucher disease is a genetic condition which causes the build-up of fatty deposits in certain organs and bones.